TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2498141
Drug: Tocainide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (400 mg, three times daily)
Study: 2498141
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg, once daily)
Study: 2498141
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atenolol and Tocainide
Study: 4929685
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg phenazocine hydrobromide (Narphen)
Study: 4929685
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulphate
Study: 29220855
Drug: NOAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC therapy (dabigatran 150 mg BID, apixaban 5 mg BID, dabigatran 110 mg BID, rivaroxaban 20 mg OD, rivaroxaban 15 mg OD, apixaban 2.5 mg OD)
Study: 28059799
Drug: B&L Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: B&L Group therapy (Ben‐Yishay & Lakin model)
Study: 28059799
Drug: S&M Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: S&M Group therapy (Sohlberg & Mateer model)
Study: 26678641
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg/d for 2 weeks
Study: 26678641
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet for 2 weeks)
Study: 18312153
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg b.i.d. (n = 17)
Study: 18312153
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg b.i.d. (n = 17)
Study: 7066166
Drug: Spironolactone 400
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 400 mg
Study: 18312153
Drug: Eplerenone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 150 mg
Study: 12672180
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 treatment
Study: 12672180
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro IL-10 treatment
Study: 10989856
Drug: Midazolam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (30 ng/mL) co-administered with ketamine
Study: 10989856
Drug: Ketamine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50, 100, or 150 ng/mL)
Study: 10989856
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Midazolam and Ketamine
Study: 9183229
Drug: Conjugated estrogens,
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens, 0.625 mg/d
Study: 9183229
Drug: Pravastatin sodium,
Normalized name: Pravastatin Sodium, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin sodium, 20 mg/d
Study: 24548114
Drug: Aspirin before
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin before and after exercise (AA)
Study: 24548114
Drug: Aspirin before
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin before and placebo after exercise (AP)
Study: 24548114
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before and aspirin after exercise (PA)
Study: 20186295
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg.kg(‐1)
Study: 17914519
Drug: Etomidate 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.1 mg.kg(‐1)
Study: 12100298
Drug: Budesonide (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (140 microg once daily)
Study: 12100298
Drug: Fluticasone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (200 microg once daily)
Study: 2382243
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (40 mg in 4 ml buffered saline)
Study: 2382243
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml of diluent solution)
Study: 24010954
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal treatment (scaling and root planing)
Study: 24010954
Drug: Community periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community periodontal treatment (one session of supragingival plaque removal)
Study: 17341712
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg of oral conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Study: 11677862
Drug: Homeopathic drugs
Normalized name: homeopathic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic drugs (Homéogène 46 and Sédatif PC)
Study: 9366318
Drug: Intravesical capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical capsaicin (1 to 2 mmol/l. in 30% ethanol in saline)
Study: 2892658
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg daily)
Study: 31308360
Drug: Delayed-release nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed-release nutrient (DRN)
Study: 17036388
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte solution on the same day as colonoscopy
Study: 17036388
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte solution on the day prior to colonoscopy
Study: 17036388
Drug: Preparation on
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation on the same day as colonoscopy
Study: 17036388
Drug: Preparation on
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation on the day prior to colonoscopy
Study: 15231912
Drug: Multivitamins with
Normalized name: MULTIVITAMINS WITH MINERALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins with iron (10 mg/day) for 3 months
Study: 15231912
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard-dose multivitamins without iron)
Study: 11231988
Drug: No lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid infusion (control)
Study: 11210867
Drug: Ranitidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine at a dosage of 1 mg/kg per day intravenously for 20 days
Study: 11783268
Drug: Qingkailing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing injection (QKLI) 120 ml/d
Study: 11783268
Drug: Qingkailing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing injection (QKLI) 160 ml/d
Study: 11783268
Drug: Qingkailing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing injection (QKLI) 200 ml/d
Study: 11783268
Drug: Lincomycin 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lincomycin 1.8 g/d
Study: 11783268
Drug: Qingkailing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingkailing injection (QKLI)
Study: 2472994
Drug: Glucagon and
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon and insulin therapy
Study: 362955
Drug: Levamisole (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50-150 mg)
Study: 31757095
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 PUFA (three 1 g capsules containing 460 mg/g EPA and 380 mg/g DHA) for 44 weeks
Study: 28440817
Drug: Sulpiride (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (800 mg p.o.)
Study: 25922903
Drug: Placebo nitrite
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nitrite cream and placebo citric acid cream applied twice daily
Study: 25922903
Drug: Low-dose treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose treatment (sodium nitrite, 3%, with citric acid, 4.5%, creams applied twice daily)
Study: 25922903
Drug: Middle-dose treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied once daily at night, with placebo applied in the morning)
Study: 25922903
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment (sodium nitrite, 6%, with citric acid, 9%, creams applied twice daily)
Study: 24607004
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) - 5×10(8) TCID50 of modified vaccinia Ankara
Study: 24607004
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) - 1×10(8) TCID50 of modified vaccinia Ankara (2 doses)
Study: 18074029
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg po bid
Study: 18074029
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg po bid
Study: 18074029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amantadine and oseltamivir
Study: 11170731
Drug: Dysport (botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport (botulinum neurotoxin type A) diluted to a final concentration of 50 U/ml, low-dose treatment cut by approximately 70%
Study: 11170731
Drug: Recommended higher
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended higher doses of Dysport
Study: 8026092
Drug: Topical aural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aural antibiotic therapy (7-day course)
Study: 8026092
Drug: Topical aural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aural antibiotic therapy administered by someone other than the patient
Study: 960794
Drug: Caffeine solution
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine solution
Study: 31498783
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg 10-minutes before induction and 0.5 μg/kg/hour maintenance infusion until end of operation)
Study: 26264648
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavior therapy (gCBT)
Study: 23118022
Drug: Antidopaminergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidopaminergic treatment (aripiprazole, haloperidol, or reserpine)
Study: 19932779
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (telmisartan + ramipril)
Study: 17684878
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of hyperbaric ropivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Study: 17684878
Drug: 11.25 mg
Normalized name: phentermine 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg of hyperbaric bupivacaine with 0.1 mg of preservative-free morphine and 0.01 mg fentanyl
Study: 11238483
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g protein in the form of very lean beef
Study: 9669811
Drug: Hybrid chemotherapy
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid chemotherapy (HYB) - CAV/PVP, 3-drug CAV on Day 1 and 2-drug PVP on Day 8, repeated every 4 weeks for up to 6 cycles.
Study: 9669811
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (SEQ) - CAV followed by PVP, 3 cycles each every 4 weeks, delivered on Days 1 and 8.
Study: 3261647
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ejection fractions 0.30 to 0.49)
Study: 3261647
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (ejection fractions > 0.69)
Study: 31665005
Drug: Advanced disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced disease with no treatment
Study: 27225598
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation plus tablet (tablet group)
Study: 24114194
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) formulations of ONO-5334
Study: 24114194
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) tablets of ONO-5334
Study: 22797880
Drug: Oral pregabalin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pregabalin, 75 mg q12 h for five consecutive days starting the night before surgery
Study: 17805093
Drug: Simulated LH+TL
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated LH+TL devices (e.g., nitrogen apartments, hypoxic tents, hypoxicator devices)
Study: 15154878
Drug: Etidronate 200
Normalized name: etidronate 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 200 mg orally before sleep on dialysis days (3 times per week)
Study: 16556138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no etidronate treatment)
Study: 11666124
Drug: Total triterpenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 6 months
Study: 22174166
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (second control group)
Study: 3058442
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg before meals and at bedtime for six weeks)
Study: 3058442
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral for six weeks)
Study: 28937255
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of whey proteins (OWIST)
Study: 26525617
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie diet therapy (LCDT)
Study: 19141576
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg daily (with adjustments to 40 mg or 120 mg as needed)
Study: 17583188
Drug: Perindopril/Indapamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/Indapamide combination (Per 2 mg/Ind 0.625 mg) for 3-6 months
Study: 11174052
Drug: riluzole 150
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole 150 mg
Study: 9296037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of malocid-sulfadiazine
Study: 3577821
Drug: Adenosine 0.07
Normalized name: Niacinamide 3.6 g in 180 mL / Adenosine 0.07 g in 180 mL TOPICAL LIQUID [VITA VOLU VOLUME BOOSTER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 0.07 mg kg‐1 min‐1 following saline
Study: 3577821
Drug: Adenosine 0.005
Normalized name: ADENOSINE 0.005 g in 13 mL TOPICAL LIQUID [Tissen ICM 10]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 0.005 mg kg‐1 min‐1 following dipyridamole
Study: 3577821
Drug: Adenosine 0.08-0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 0.08-0.09 mg kg‐1 min‐1 following saline
Study: 24045438
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (FS) spray
Study: 20884422
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin 0.75 mg/kg
Study: 20884422
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin 0.75 mg/kg in patients with ACS
Study: 20884422
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) in patients with ACS
Study: 12559642
Drug: Interim analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interim analysis of a new drug for autoimmune disease
Study: 7692189
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) at 10.5 +/- 1.2 micrograms/kg per day
Study: 24256166
Drug: 1.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg Ni/week
Study: 17474806
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg
Study: 16514812
Drug: Lisinopril administration
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril administration
Study: 9625099
Drug: Elevated AGP
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated AGP (> or = 1 g/L)
Study: 9625099
Drug: Elevated CRP
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated CRP (> or = 5 mg/L)
Study: 8170176
Drug: Aspirin preoperatively
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin preoperatively
Study: 8170176
Drug: Heparin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin followed by warfarin sodium
Study: 1331724
Drug: Oatbran (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oatbran (60 g per day)
Study: 23837502
Drug: Submerged implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged implant placement
Study: 23837502
Drug: Transmucosal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmucosal implant placement
Study: 24409075
Drug: Nedaplatin (NDP)
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin (NDP) 80‐100 mg/m² iv on day 1 + leucovorin (CF) 100 mg/m² iv on days 1‐5 + 5‐fluorouracil (5‐FU) 500 mg/m² iv on days 1‐5
Study: 22151509
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (the pill)
Study: 19393409
Drug: Silver nitrate
Normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silver nitrate cautery followed by antiseptic cream for 4 weeks
Study: 19393409
Drug: Sham cautery
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cautery followed by antiseptic cream for 4 weeks
Study: 17370660
Drug: Telescopic crowns
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telescopic crowns on two endosseous implants
Study: 15331202
Drug: Oolong tea
Normalized name: oolong tea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oolong tea (1000 ml)
Study: 8143398
Drug: Inhaled marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled marijuana smoke (1 marijuana cigarette containing 1.54% delta 9‐tetrahydrocannabinol)
Study: 8143398
Drug: Inhaled marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled marijuana smoke
Study: 2895664
Drug: sublingual lormetazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual lormetazepam 2.5 mg
Study: 2895664
Drug: i.v. diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diazepam 10 mg
Study: 30656849
Drug: Ethanol treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol treatment
Study: 28939223
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) + Whole-brain radiation therapy (WBRT)
Study: 23617135
Drug: Traditional restoration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional restoration methods with traction treatment
Study: 18547177
Drug: NASHA 100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA 100,000 gel particles/mL filler with retreatment at 4.5 months
Study: 18547177
Drug: NASHA 100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA 100,000 gel particles/mL filler with retreatment at 9 months
Study: 29515036
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment for 14 days
Study: 7871380
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subnitrate, oxytetracycline, metronidazole) for 2 weeks
Study: 3370308
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg as aqueous solution
Study: 3370308
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg as Tablet A (fast dissolution)
Study: 3370308
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg as Tablet B (slow dissolution)
Study: 3370308
Drug: Furosemide tablets
Normalized name: Furosemide Tablets
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide tablets (both A and B)
Study: 26860016
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution at a 'keep vein open' rate (Group E)
Study: 23325481
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR 60 mg once daily for 10 days plus metformin 500 mg twice daily for 3.5 days